Aktienanalyse zu Anteris Technologies Global Corp (AVR)AVRAnteris Technologies Global Corp

Anteris Technologies Global Corp. is a structural heart company, which is engaged in providing cardiac care by science-driven and measurable advancements to restore heart valve patients to healthy function. Its lead asset, the DurAVR Transcatheter Heart Valve System (THV) consists of a single-piece, biomimetic valve made with its ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. DurAVR THV is a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. DurAVR THV’s single-piece design mimics the native anatomy of a human aortic valve, as compared to traditional three-piece aortic valves. The Company's ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. Its ComASUR delivery system is a physician-developed balloon expandable delivery system. It operates in the Healthcare sector.

Anteris Technologies appears to be a good buy right now due to its current price of $8.74, which is significantly below analyst price targets ranging from $15 to $18, indicating potential upside. Additionally, the company has shown a strong gross margin of 76.91% in Q2 2026, suggesting efficient operations. However, the main risk is the ongoing net losses, with a reported EPS of -0.30 in the last earnings report, which could impact investor sentiment.